Abstract: The present disclosure provides for and relates to the identification of novel biomarkers for diagnosis and prognosis of prostate cancer or the biochemical reoccurrence of prostate cancer. The biomarkers of the invention show altered methylation levels of certain CpG loci relative to normal prostate tissue, as set forth.
Type:
Grant
Filed:
March 13, 2014
Date of Patent:
January 31, 2023
Assignees:
HUDSONALPHA INSTITUTE FOR BIOTECHNOLOGY, THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY
Inventors:
Richard M. Myers, James D. Brooks, Marie K. Kirby
Abstract: The present disclosure provides for and relates to cancer treatment based on the identification of novel biomarkers for diagnosis and prognosis of prostate cancer or the biochemical reoccurrence of prostate cancer. The biomarkers of the invention show altered methylation levels of certain CpG loci relative to normal prostate tissue, as set forth.
Type:
Grant
Filed:
October 29, 2019
Date of Patent:
August 10, 2021
Assignees:
HudsonAlpha Institute for Biotechnology, BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY
Inventors:
Richard M Myers, James D Brooks, Marie K Kirby
Abstract: The present disclosure provides for and relates to the identification of novel biomarkers for diagnosis and prognosis of prostate cancer or the biochemical reoccurrence of prostate cancer. The biomarkers of the invention show altered methylation levels of certain CpG loci relative to normal prostate tissue, as set forth.
Type:
Grant
Filed:
December 22, 2015
Date of Patent:
December 10, 2019
Assignees:
HudsonAlpha Institute for Biotechnology, Board of Trustees of the Leland Stanford Junior University
Inventors:
Richard M. Myers, James D. Brooks, Marie K. Kirby
Abstract: A blocking nucleic acid for use in reducing the abundance of a non-target micro-RNA (miRNA) in an miRNA library is provided, including: a single-stranded complementary region at one of the 5? end of the blocking nucleic acid or the 3? end of the blocking nucleic acid, that anneals with a binding region at a first end of the unwanted miRNA; a hairpin loop forming region or other double-stranded region adjacent to the complimentary region, in which all of the terminal ends of the blocking nucleic acid except one are unavailable to participate in ligase reactions. Methods and kits for using the blocking nucleic acid are also provided.
Abstract: Disclosed is a method for amplifying and detecting polynucleotides which can provide sensitive, specific detection of multiple targets from a clinical specimen within a relatively short time.